Nanjing Vcare's Production Subsidiary Tianshu Pharmaceutical Selected as 2025 Hubei Technology Innovation "New Species" Gazelle Enterprise

2025-08-06

　　Recently, the Hubei Provincial Department of Science and Technology announced the2025 Hubei Technology Innovation "New Species" Enterprise List for intended inclusion. Hubei Tianshu Pharmaceutical Co., Ltd. (Tianshu Pharmaceutical), the production base subsidiary of Nanjing Vcare Pharmatech Co., Ltd. (Nanjing Vcare), has stood out with its outstanding scientific innovation capabilities and high-growth performance, successfully being selected as a Hubei Technology Innovation "New Species" Gazelle Enterprise. This signifies that Tianshu Pharmaceutical has received high-level governmental recognition and affirmation in terms of growth speed, innovation capacity, specialized domain expertise, and development potential.

　　Tianshu Pharmaceutical consistently attaches great importance to technological innovation work, continuously promoting the research, development, and introduction of cutting-edge engineering technologies. Currently, Tianshu Pharmaceutical has achieved over30 technological innovation accomplishments, including: 5 invention patents; 28 utility model patents; 2 PCT international patents. It has been successfully selected as: Hubei Provincial Specialized, Refined, Distinctive, and New SME; Hubei Provincial Technology-based SME. Approved to establish: Hubei Provincial SME Technology Center; Hubei Provincial High-End API and Pharmaceutical Intermediate CDMO R&D and Pilot Production Platform, etc.. And has smoothly passed the integrated triple certification for: GB/T 19001-2016/ISO Quality Management System; GB/T 24001-2016/ISO Environmental Management System; GB/T 45001-2020/ISO Occupational Health and Safety Management System.

　　Moving forward, Tianshu Pharmaceutical will redouble its efforts to: Continue increasing R&D and innovation investment; Continuously enhance technological innovation capabilities; Persist in independent innovation; Strive to improve the company's market competitiveness centered on differentiated technologies; Aim to ascend to a higher-tier "New Species" enterprise status.

Next

Nanjing Vcare Honored as "Best Customer Satisfaction CRO Enterprise"